Cargando…

Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells

Currently, there is no appropriate treatment option for patients with sorafenib-resistant hepatocellular carcinoma (HCC). Meanwhile, pronounced anticancer activities of newly-developed mitochondria-accumulating self-assembly peptides (Mito-FF) have been demonstrated. This study intended to determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Tae Ho, Jeena, M. T., Kim, Ok-Hee, Kim, Kee-Hwan, Choi, Ho Joong, Lee, Kyung Hee, Hong, Ha-Eun, Ryu, Ja-Hyoung, Kim, Say-June
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806888/ https://www.ncbi.nlm.nih.gov/pubmed/33441650 http://dx.doi.org/10.1038/s41598-020-79536-z

Ejemplares similares

Novel Therapeutic Application of Self-Assembly Peptides Targeting the Mitochondria in In Vitro and In Vivo Experimental Models of Gastric Cancer
por: Kim, Dong Jin, et al.
Publicado: (2020)

Combining Everolimus and Ku0063794 Promotes Apoptosis of Hepatocellular Carcinoma Cells via Reduced Autophagy Resulting from Diminished Expression of miR-4790-3p
por: Choi, Ho Joong, et al.
Publicado: (2021)

Antioxidant action of hypoxic conditioned media from adipose-derived stem cells in the hepatic injury of expressing higher reactive oxygen species
por: Hong, Ha-Eun, et al.
Publicado: (2019)

Cancer-mitochondria-targeted photodynamic therapy with supramolecular assembly of HA and a water soluble NIR cyanine dye
por: Thomas, Ajesh P., et al.
Publicado: (2017)

Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells
por: Park, Jung Hyun, et al.
Publicado: (2019)

Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis
por: Park, Jae Woo, et al.
Publicado: (2020)

Enhanced Therapeutic Potential of the Secretome Released from Adipose-Derived Stem Cells by PGC-1α-Driven Upregulation of Mitochondrial Proliferation
por: Lee, Jaeim, et al.
Publicado: (2019)

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy
por: Jeena, M.T., et al.
Publicado: (2019)

Enzyme-instructed morphology transformation of mitochondria-targeting peptide for the selective eradication of osteosarcoma
por: Jeena, M. T., et al.
Publicado: (2022)

Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy
por: Lee, Sang Chul, et al.
Publicado: (2018)

Mitochondria localization induced self-assembly of peptide amphiphiles for cellular dysfunction
por: Jeena, M. T., et al.
Publicado: (2017)

Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells
por: Kim, Kee-Hwan, et al.
Publicado: (2019)

A novel antifibrotic strategy utilizing conditioned media obtained from miR-150-transfected adipose-derived stem cells: validation of an animal model of liver fibrosis
por: Paik, Kwang Yeol, et al.
Publicado: (2020)

PGC‐1α is downregulated in a mouse model of obstructive cholestasis but not in a model of liver fibrosis
por: Park, Jung Hyun, et al.
Publicado: (2020)

Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells
por: Kim, Jong-Ok, et al.
Publicado: (2016)

A Novel Hepatic Anti-Fibrotic Strategy Utilizing the Secretome Released from Etanercept-Synthesizing Adipose-Derived Stem Cells
por: Han, Jae Hyun, et al.
Publicado: (2019)

Harnessing adipose-derived stem cells to release specialized secretome for the treatment of hepatitis B
por: Kim, Hee Ju, et al.
Publicado: (2021)

A Novel Way of Preventing Postoperative Pancreatic Fistula by Directly Injecting Profibrogenic Materials into the Pancreatic Parenchyma
por: Lee, Sang Chul, et al.
Publicado: (2020)

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis
por: Chu, Hee Ho, et al.
Publicado: (2020)

Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022)

Superior gallstone dissolubility and safety of tert-amyl ethyl ether over methyl-tertiary butyl ether
por: You, Dong Do, et al.
Publicado: (2019)

Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells
por: Son, Yeonghoon, et al.
Publicado: (2021)

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions
por: Lee, Sae Hwan, et al.
Publicado: (2015)

Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
por: Kim, Tae Suk, et al.
Publicado: (2017)

Necrotizing fasciitis associated with sorafenib treatment
por: Kang, Ho Won, et al.
Publicado: (2019)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
por: Jeong, Soung Won, et al.
Publicado: (2013)

A novel strategy to promote liver regeneration: utilization of secretome obtained from survivin-overexpressing adipose-derived stem cells
por: Kim, Cho-Hee, et al.
Publicado: (2021)

Determination of optimized oxygen partial pressure to maximize the liver regenerative potential of the secretome obtained from adipose-derived stem cells
por: Lee, Sang Chul, et al.
Publicado: (2017)

Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy
por: Kim, Pyeong Hwa, et al.
Publicado: (2019)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma
por: Kim, Gwi Eon, et al.
Publicado: (2017)

Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis
por: Kim, Gun Ha, et al.
Publicado: (2021)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis
por: Jo, Hyun Ho, et al.
Publicado: (2020)

Mitochondria in reproduction
por: Kang, Min-Hee, et al.
Publicado: (2023)

Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib
por: Jeong, Hee Kyoung, et al.
Publicado: (2011)

Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma
por: Chow, Pierce K. H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e1m3hqvqns59ulc87a4v6c48kr